Podium to Practice: Chicago 2025 – Lung: CheckMate 816

Podium to Practice: Chicago 2025 – Lung: CheckMate 816

Podium to Practice: Chicago 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Barb Melosky

Icon Chair Speaker

Speakers

Dr. Rosalyn Juergens

Dr. Kevin Jao

Studies / Trials Discussed

LBA8000 – Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816.

This program has been made possible through unrestricted support from Boehringer Ingelheim.

Studies/trials discussed:

LBA8000 – Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816.
Tagged